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Summary One hundred and thirty-seven lung cancer patients (123 non-small-cell lung cancers (NSCLC), 10
small-cell lung cancers (SCLC) and four carcinoid tumours) who underwent surgery in an attempt at complete
resection were prospectively entered in a study whose aim was to determine the prognostic significance of a
hypodiploidy or a multiploidy pattern of tumour cell DNA content and a high immunohistochemical reactivity
of Ki-67, a nuclear antigen related to the cell cycle. Indirect immunoperoxidase reactivity of Ki-67 on frozen
tumour tissue sections was evaluated both visually, using a classical semiquantitative scale, and by means of a
computer-assisted image processor. Cell DNA content analysis was done using static computer-assisted
cytometry on tumour cytological prints stained by the pararosaline Feulgen-Schiff technique. The ploidy was
characterised for each tumour by DNA index (DI), percentage of hypodiploid cells and type of DNA content
histogram (near diploid, hyperdiploid, hypodiploid and multiploid). Ki-67 immunostaining was negative in 64
tumours (48%) and positive in 69 (52%). DNA histogram classification disclosed 57 (42%) near diploid
tumours. Among the 80 (58%) aneuploid tumours, 16 were hypodiploid, 44 hyperdiploid and 20 multiploid.
The prevalence of both a positive Ki-67 immunostaining and an aneuploid DNA histogram differed according
to histology as SCLC demonstrated a higher frequency of both features when compared with NSCLC and
carcinoid tumours. On the other hand, Ki-67 immunostaining and ploidy did not significantly differ according
to degree of differentiation, nodal status and Mountain's stage grouping. The percentage of cells in the
hypodiploid modal DNA was significantly higher for tumours which demonstrated a high Ki-67
immunostaining, suggesting a link between growth fraction and DNA content abnormalities. In univariate
analysis, survival did not differ significantly according to either the Ki-67 immunohistochemical reactivity or
the DNA index. Patients with a hypodiploid tumour had a shorter survival than patients with other DNA
histogram patterns but, owing to the low frequency of hypodiploidy, this difference did not reach statistical
significance. In Cox's proportional hazard model, an SCLC histology, an advanced tumour status, a positive
nodal status and a hypodiploid tumour (hazard ratio: 2.070; 95% confidence interval 1.041-4.116) were
significant determinants of survival. We conclude that hypodiploidy in lung cancer is a distinct DNA content
abnormality as it contributes significantly to prognosis. Neither visually assessed nor computer-generated Ki-67
immunostaining measurements significantly determine prognosis.
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Ploidy status predicts disease-free intervals and short-term
survival of numerous solid tumours (Friedlander et al., 1984;
Barlogie et al., 1983). In lung cancer, the prognostic value of
ploidy is controversial. The effect of ploidy status on patient
outcome has been investigated particularly in non-small-cell
lung cancers (NSCLCs), a group of different histologies
including squamous cell carcinoma (SQC), adenocarcinoma
and large-cell carcinoma (LCC). Although authors from
different laboratories have suggested that patients presenting
an aneuploid tumour have a shorter survival than patients
presenting a nearly diploid tumour (Blondal et al., 1981;
Volm et al., 1985; Zimmerman et al., 1987; Salvati et al.,
1988; Dazzi et al., 1990), others did not find such a difference
(Bunn et al., 1983; Cibas et al., 1989; Cheon et al., 1993). It is
noteworthy that aneuploidy defines a heterogeneous group of
tumours differing by their patterns of DNA histograms,
namely: hyperdiploidy, hypodiploidy and multiploidy
(Barlogie et al., 1980). In a previously published work we
determined ploidy status using static computer-assisted
cytometry in surgically resected NSCLC and we found that
hypodiploidy and multiploidy are detectable abnormalities of
DNA content (Simony et al., 1990). As other authors
studying multiple myeloma (Smith et al., 1986) or breast
cancer (Coulson et al., 1984) demonstrated that these
particular DNA histograms characterise patients suffering
from malignancies with very aggressive clinical behaviour, we
hypothesised that the prognostic significance of aneuploidy
might be related to hypodiploidy or multiploidy instead of
whole aneuploid group.
In the same above-mentioned study we analysed tumour
growth fraction by means of computer-assisted image
processor measurements of the immunohistochemical reactiv-
ity of Ki-67, a nuclear antigen expressed throughout the cell
cycle (Gerdes et al., 1984). The Ki-67 immunostaining was
significantly higher in hypodiploid and multiploid NSCLC
(Simony et al., 1990). Both Ki-67 growth fraction and ploidy
were independent of stage of the disease. Thus, ploidy and
growth fraction in surgically resected NSCLC are putative
prognostic variables.
The aim of the present prospective study was to determine:
(1) any relationship between ploidy, Ki-67 immunostaining,
histology and disease stage at time of surgery; (2) the
prognostic significance of hypodiploidy and multiploidy; and
(3) the relationship between survival and both computer-
generated and visually determined Ki-67 immunohistochem-
ical reactivity.
Materials and methods
Patients
One hundred and thirty-seven previously untreated lung
cancer patients referred to both Montpellier University
Hospital and the Thoracic Surgery Unit of Toulon Hospital
between April 1987 and January 1994 were prospectively
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1996Table I Patients' characterisitics
No
M/F
Mean age (standard deviation range)
Histologies
Squamous cell carcinoma
Adenocarcinomas
Large-cell carcinoma
Small-cell lung cancer
Carcinoid
Performance status
0
1
2
Undetermined
Nodal status
NO
NI
N2
Tumour status
TI
T2
T3
T4
Undetermined (open and cosed)
Stage of disease
I
II
IV (Ml, haematogeneous metastasisa)
Incompletely defined (open and closed)
Resection type
Lobectomy
Pneumonectomy
Open and cosed
Resection quality
137
122/15
62 (10, 31-84)
85
34
4
10
4
74
43
19
1
70
25
42
22
66
34
14
1
47
19
47
13
10
1
58
70
9
Complete 112
Incomplete 95
aTen patients were operated upon despite concomitant metastatic
disease (ipsilateral lung metastases or previously surgically resected
solitary brain metastasis).
entered in the study (Table I). All lung tumours were
analysed according to the latest WHO classification (WHO,
1982) by light microscopy following haematoxylin-eosin
staining of surgical specimens. Degree of differentiation was
defined as previously published (Simony et al., 1990).
Among them were 123 non-small-cell lung cancers, 10
small-cell lung cancers and four carcinoid tumours. The
main reason for primary surgery in the nine SCLC was the
lack of available histology before surgical procedure. In our
institution operable SCLC patients usually represent less
than 5% of the entire SCLC population. Performance
status (PS) was estimated according to the Eastern
Cooperative Oncology Group (ECOG). Staging was
carried out by exhaustive procedure (Table I) according
to the fourth edition of the UICC TNM classification
(Sobin et al., 1987) and the Mountain's stage grouping
(Mountain, 1986). For all patients staging procedure
included clinical examination, standard chest radiography,
computed tomographic (CT) scan of chest and upper
abdomen, fibreoptic bronchoscopy, liver sonography and
bone scanning. Brain CT scan was done only if clinically
required. All patients presented a respiratory function
compatible with surgical resection.
Surgery
A thoractomy was scheduled in an attempt at curative
resection and mediastinal lymph node dissection. All lymph
nodes were carefully identified according to the American
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Thoracic Society map of regional pulmonary nodes (Tisi et
al., 1982). A complete resection was defined as resection of all
macroscopic disease and normal histology of the margin.
Other resections were considered as incomplete ones.
Pathological examination of all surgical specimens contrib-
uted to establishing the definite pTNM staging.
Immunohistochemistry
Tissue preparation During the surgical resection, a specimen
ofthe tumour from a non-necrotising area was deep frozen in
liquid nitrogen until a histochemical study was performed.
The immunostaining was done on 5-,um-thick frozen tissue
sections. Sequential sections were obtained by means of an
automatic cryostat (Cryocut-Bright, Shandon, UK).
Antisera source Antibody Ki-67 (Dakopatts, Glostrup,
Denmark) is a mouse IgGI monoclonal antibody raised
against human proliferative cells. The Ki-67 related antigen is
expressed in GIA, GIB, S, G2 and M cells but is absent in Go
cells (Gerdes et al., 1984).
Immunohistochemical reactions Indirect immunoperoxidase
technique was carried out using the biotin-streptavidin-
peroxidase system following the three stage procedure (Hsu et
al., 1981). Control slides were prepared with substitution of
the primary MAb with similar dilution of an irrelevant mouse
antibody of the same isotype (Dako, Glostrup, Denmark).
The immunohistochemical reaction was analysed without any
knowledge of the clinical data.
Analysis of the Ki-67 immunohistochemical reactions The
immunohistochemical reaction was first visually evaluated
using the following semi-quantitative scale:
Class Percentage of stained nucleus
0 <2%
1 2-25%
2 25-30%
3 >50%
Computer-assisted image analysis was performed in order
to quantitate the immunoperoxidase reaction (Bacus et al.,
1987). The immunostaining quantitative analysis was done by
means of a computer-assisted image processor (Opfermann et
al., 1987) (Systeme d'analyse microphotometrique a balayage
automatique; TITN, Grenoble, France). This microcomputer-
based system is configured with a standard microscope
(Polyvar; Richert Jung, Cambridge, UK), a colour video
camera (Sony Corporation, Japan), an image analysis
processor (TSBC, TITN) and an 80486 computer. A
program developed to analyse the immunostaining tissue
sections was used (Charpin et al., 1986) (oestrogen receptor
immunocytochemical assay; TITN). This program quantitates
intensity and distribution of immunostaining in haematox-
ylin-counterstained tissue sections. Acquisitions by the colour
image processor were done through blue and red filters. Ki-67
immunostaining was analysed as a false red colour, whereas
counterstained cells were analysed as a false blue colour. For
each preparation, optical density thresholds were determined
using real microscopic images of the analysed field as
reference.
Measurements of Ki-67 immunostaining were done at
25 x (magnification 250 x). Fields analysed were randomly
selected by movements of an automatic motorised plate
which scanned tumour tissue preparations on two perpendi-
cular axes. Twenty fields were analysed for each section by
the image analysis processor. According to the surface of
tumour tissue preparation, these 20 fields represented from
30% to 60% of the whole section. Index of stained nuclear
surface and integrated optical density (IOD) were expressed
in AU. Controls of immunostaining quantitative analysis
reproducibility were carried out as previously described in
detail (Simony et al., 1990).Hyodiploidy, Ki-67 and prognosis of lung cancer
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Cell DNA content analysis
Tissue preparation A cytological print from each specimen
was air dried. Slides were fixed in formaldehyde-alcohol
solution for 10 min then washed three times in alcohol and
stained by the pararosaline Feulgen-Schiff technique (Kenji,
1971).
Computer-assisted cytometry The stoichiometric reaction
wsa analysed using the computer-assisted image processor
(Systeme d'analyse microphotometrique a' balayage automa-
tique; TITN). For each specimen, cell DNA content analysis
was carried out on 300 randomly selected malignant cells.
The nuclear DNA values were computerised in order to
produce histograms. The cell DNA content was expressed in
c-units with 2c representing the mean value of normal diploid
control cells (normal hepatic tissue). Ploidy was determined
for each specimen using DNA index which represents the
ratio of the cell DNA content of tumour GO/, cells to the
diploid Go/, peak (2c). Thus, a DNA index equal to 1 defined
near diploid tumours.
DNA histogram analysis The DNA histograms were
classified into four types (Figure 1): a, tumour Go/, cells in
the near diploid region (2c, DNA index= 1), with few G2M
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tumour cells in the tetraploid region (4c); b, hyperdiploid
tumour Go/, cells (DNA index> 1.2); c, hypodiploid tumour
Go/, cells (DNA index , 0.8), with a hypodiploid peak
containing at least 20% of cells; d, evidence of multiploid
tumour cells with multiple aneuploid peaks, some of them in
the octaploid region (8c). In addition, the percentage of cells
in the hypodiploid modal DNA (percentage of hypodiploid
cells DNA index<0.8) was calculated for each histogram.
Study design
This was a bicentric non-randomised prospective study.
Neither chemotherapy nor radiotherapy was carried out
before surgical resection. Evaluation of growth fraction and
cell DNA content were done independently and without
knowledge of the pTNM stage. Ploidy was determined in all
cases whereas optical semi-quantitative evaluation of Ki-67
immunostaining was not done in four cases. There was one
planned interim analysis of survival done when 97 patients
entered the study. This interim analysis demonstrated no
survival-Ki-67 relationship whatever the analysis, either
visual or quantitative. Thus, only visual analysis was
performed thereafter.
The primary end point of this study was to determine the
prognostic significance of the following parameters: Ki-67
b
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Figure 1 DNA histogram analysis. The DNA histograms were classified into four types: a, tumour GO/, cells in the near diploid
region; b, hyperdiploid tumour GO/, cells; c, hypodiploid tumour GO/, cells; d, evidence of multiploid tumour cells with multiple
aneuploid peaks.
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growth fraction evaluated both semi-quantitatively and
quantitatively: patterns of DNA histogram (near diploid.
hyperdiploid. hypodiploid. multiploid): normal (>0.8 and
<1.2) or abnormal () 1.2 or <0.8) DNA index: percentage
of cells in the hypodiploid channel. Survival was calculated
from the date of surgery to the date of death and none of the
patients was lost to follow-up. Median follow-up was 60
months. Probability of surVival was estimated by the
Kaplan-Meier method (Kaplan and Meier. 1958). Single
variable survival analyses were done by means of Wilcoxon
and log-rank tests.
Multivariate regression was done with the Cox's model
(Cox. 1972). This model was written after a Boolean codage
of the significant variables: categorical variables (such as Ki-
67 immunostaining) were transformed into binary variables
(0. negative: or 1. positive). The number of levels of a
Boolean variable needed to describe a predictive factor is one
less than the categories of that factor inasmuch as its baseline
level is defined bv setting the value of each of the Boolean
variables to zero. The significance of the effect of a given
factor was assessed by determining whether or not the
coefficient assigned to one or more of its categories was
sufficiently different from zero.
The secondary end point of this study was to identif) an)
relationship between these parameters and other clinical
variables such as pTNM. Non-parametric tests were used to
analyse the latter end point (the distribution of qualitative
variables between groups was compared using chi-square test
and Fisher's exact test. whereas quantitative variables were
compared using the Mann-Whitney U-test and Kruskal-
Wallis (KW) test: a P-value<0.05 was considered as
significant).
Results
Distribution of Ki-67 immunostaining according to pathology
and pTVMf stage
Positive Ki-67 immunostaining was strictly restricted to the
cell nuclei. The distribution of the staiimng involved
nucleolus. nuclear membrane and nucleoplasm shoWing a
great variability (Figure 2). Visually. the percentage of cells
with nuclear Ki-67 positive varied from less than 2% to over
50%. Four specimens w-ere not evaluable bv Ki-67
immunostairing owing to insufficient tumour cells or crush
artefacts. Of the remaining 133 specimens. 64 (48%) tumours
showed no significant Ki-67 immunostaining (class 0)
whereas reactiv"ity of classes 1. 2 and 3 was observed in
39%. 11% and 2% of the patients respectively. Computer-
generated quantitative analysis showed no detectable staining
in the 64 tumour specimens with less than 2% (class 0) Ki-67-
positive cells. whereas both the index of stained nuclear
surface and IOD varied widely (range 3-739 AU and 9-
38716 AU respectively) in the visually positive tumours
(classes 1-3).
The frequency of Visually assessed classes 1 -3 Ki-67
immunostaiing significantly differed according to histology
as none of the carcinoid tumours showed any staining.
whereas 52% of NSCLC and 75% of SCLC showed a
positive reactivity of Ki-67 (x =6.03: P<0.05). However.
when the analysis was limited to the SCLC and NSCLC
groups the difference in frequency of a positive Ki-67
immunostaiing did not reach statistical significance
(X = 1.52: P=0.21). Converselv. the Ki-67 immunostaining
did not differ significantly according to degree of differentia-
tion. nodal status and Mountain's stage grouping. Neither
the computer-generated index of stained nuclear surface
distribution nor the integrated optical density varied
significantlv according to the above-mentioned pathological
and clinical variables. There was no relation of performance
status to the Ki-67 growth fraction w-hether the latter variable
was evaluated Visually or quantitatively.
Ploidv according to pathology and pT.NM_ stage
DNA histogram classification disclosed 57 (42%) near
diploid tumours. Among the 80 (58%) aneuploid tumours.
16 were hypodiploid. 44 hyperdiploid and 20 multiploid. The
distribution of tumours by DNA index is shown in Figure 3.
According to histology. the frequency of an aneuploid DNA
histogram differed as it was the highest in SCLC (8 10) and
the lowest in carcinoid tumours (1 4). whereas 44% (54 123)
of the NSCLC were aneuploid (x=5.58. P=0.06). Patient
groups defined by degree of tumour differentiation. stage
group and nodal status did not differ significantly either by
their DNA index or their DNA histogram classification. In
particular. the hypodiploid DNA pattern did not correlate
with an advanced stage.
Relation of Ki-67 growsth fraction to ploidv
The percentage of cells in the hypodiploid modal DNA w-as
siznificantly higher for tumours demonstrating a high Ki-67
imMunostaining as determiined visually [median (IR): 50% (3-
8.5) and 7.50o (5-15) for class 0 and classes 1-3 Ki-67
immunostaining respectively: Mann-Whitney U-test.
P<0.05: Figure 4].
U-niv ariate survival analyses
Univariate analysis showed that patients with either an SCLC
histology. a positive lymph node status. a T3 -4 tumour
modal DNA of GI.J(G tumour cells
Ch 0
CD
.)-
0
a)
.0-
E
z
Figre 2 Indirect immunopero_xidase reactivity of monoclonal
antibodv Ki-67 on poorlv differentiated SQC tissue section. Some
cells demonstrate variable nuclear staining involving nucleoplasm
and or nuclear matrix (original magnification x 560).
0.5 0.7 1.0 1.1 1.3 1.5 1.7 1.9 2.2 2.4 2.6 2.8
DNA index
Figure 3 Frequency distribution of tumours by their DNA
index. For multiploid tumours the DNA index of the main
aneuploid peak has been taken into account.
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status, an advanced stage (III or IV of Mountain's stage
grouping) or an incomplete resection proved to have a
shorter survival when compared with the respective opposite
level of each variable (NSCLC histology, negative lymph
node status, TI-2 tumour status, I or II disease, complete
resection; Table II). Patients with a 1 or 2 performance status
had a shorter survival in comparison with patients with a
good performance status, although this difference did not
reach statistical significance.
Survival did not differ significantly according to the Ki-67
immunohistochemical reactivity. In particular, prognosis did
25
C._
0-;
-0
0.
I
.5
10
5
0
Ki-67
positive
Mann-Whitney: P
<0.05
Ki-67
negative
Figure 4 Relation of Ki-67 immunoreactivity (visually assessed)
vs percentage of cells in the hypodiploid modal DNA. Horizontal
bar, median value; columns, interquartile range; vertical bar, 5th _
95th percentile range.
not vary significantly according to the computer-generated
quantitative analysis (index of stained nuclear surface and
integrated optical density; Figure 5). Conversely, there was a
relationship between survival and the visually assessed Ki-67
growth fraction inasmuch as the higher the class of staining,
the worse the median survival became but this effect did not
reach statistical significance (log-rank, P=0.3; Figure 6).
Survival did not differ significantly when patients with a
normal DNA index were compared with patients with an
abnormal DNA index (respective median survival: 32 and 35
months; log-rank, P=0.37; Wilcoxon, P=0.44). Patients with
a hypodiploid tumour had a shorter survival than patients
with other DNA histogram patterns but, owing to the low
frequency of hypodiploidy, this difference did not reach
statistical significance (Figure 7). A multiploidy or a
hyperdiploidy had no effect on prognosis.
Multivariate analysis
Cox's proportional hazard model analysis was written after a
Boolean codage of the variables reaching a P-value <0.3 in
the univariate analyses. For each variable, the proportional
hazard assumption was tested graphically. An SCLC
16
U,
0
co
.0
0 .- QL
Table II Univariate analyses
Median
survival P-value
Factor and level (months) Wilcoxon Log-rank
Histology
NSCLC 35 0.0001 0.0001
SCLC 7
Nodal status
NO 64 0.0001 0.0001
NI-2 13
Tumour status
Ti-2 43 0.0014 0.0017
T3-4 14
Stage
I and II 64 0.0001 0.0001
III and IV 13
Resection quality
Complete 40 0.0001 0.0001
Incomplete 9
Performance status
0 35 0.26 0.39
1-2 27
Ki-67 index of stained nuclear surface
0 AU 40 0.71 0.57
>0 and <100 AU 39
> 100 AU 31
Ki-67 semi-quantitative evaluation
0 40 0.35 0.30
1 34
2 24
3 9
DNA index
Normal range 32 0.44 0.37
Out of normal range 35
Ploidy
Non-hypodiploid 35 0.39 0.24
Hypodiploid 24
1.0
0.8
0.6
0.4
0.2
0
0 20 40 60 80 100
Months
Stained nuclearsurface n Median survival Censored (%)
0AU 64 40 53
>Oand<100AU 21 39 38
..100AU 12 31 25
Figure 5 Probability of survival of lung cancer patients
according to quantitative (computer generated) measurement of
Ki-67 immunostaining. ( ), 0 AU; ( )>0 and <100 AU; (-
- -), > 100 AU.
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Months
IHC reaction categories n Median survival
0 64 40
1 52 34
2 14 24
3 3 9
Figure 6 Probability of survival of lung cancer patients
according to semi-quantitative (visually) assessment of Ki-67
immunostaining. IHC reaction categories: ( ), 0; ( ), 1;
(....), 2; (- - -), 3.
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5S, a positive nodal status firstly, the Ki-67 staining in lung cancer is known as
variables retained in the heterogeneous (Simony et al., 1990). This might jeopardise
nants of survival (Table the evaluation of growth fraction of the whole tumour. In
el was run again in the order to reduce this phenomenon we used a computer-
les were retained (except generated quantitative measurement of Ki-67 immunostain-
hazard ratio. ing. However, both this computer analysis and the classical
semi-quantitative visual scale of immunoreaction failed to
demonstrate any relationship between prognosis and Ki-67.
Secondly, a high Ki-67 growth was mainly seen in SCLC.
Thus, the multivariate analysis only retained the histology as
*acterises poor prognostic a prognostic factor as it is the main determinant.
sitivity to chemotherapy DNA content analysis has been proposed to assess cell
are different methods of kinetics, as the DNA histogram allows the identification of
n. All consist in detecting the percentage ofcells in S-phase. However, the assessment of
hymidine labelling index S-phase is frequently hampered by the overlap between
valuation of S-phase are aneuploid tumour cell population and diploid non-malignant
they require in vivo or in cell population. Thus, in human malignancies, DNA content
olites [tritiated thymidine analysis is mainly used to evaluate the occurrence of
1989; Gratzner, 1982)]. aneuploid cell population, an abnormality known to
re been developed which characterise malignant cells (Barlogie et al., 1980). Flow
the percentage of cells cytometry is considered as the standard method to analyse
is. The two most widely DNA content histograms after propidium iodine staining of a
ction of Ki-67 (Gerdes et single-cell suspension. This method takes into account
lear antigen (PCNA), an thousands of cells. Static cytometry has been proposed as
-ase delta (Theunissen et an alternative method. It analyses cytological prints of the
tion and the BrdUrd S- tumour after Feulgen staining. This second method only
correlated in lung cancer analyses a few hundred cells. Although this number is lower
than the one analysed by flow cytometry, the computer-
Ki-67 growth fraction in assisted image processor is able to distinguish between
Lblished as some studies tumour cells to be analysed and tumour-infiltrating
dictive of poor survival lymphocytes. In addition, studies carried out in order to
1993), whereas others did compare the two methods demonstrated the reliability of
kar et al., 1991). In our ploidy analysis using static cytometry (Friedlander et al.,
Lto predict prognosis. In 1984). Thus, static computer-assisted cytometry is considered
f prognosis did not retain as a reliable means of analysing ploidy in situ.
a putative prognostic In multiple myeloma and in breast cancer attention has
ypotheses to explain this been paid to the occurrence of two particular types of
not mutually exclusive: aneuploid status, namely multiploidy and hypodiploidy
(Smith et al., 1986; Coulson et al., 1984). The second DNA
pattern is associated with a poor prognosis and a poor
sensitivity to chemotherapy. In addition, a link has been
suggested between hypodiploidy and growth fraction (Simony
Wilcoxon P= 0.39 et al., 1990). In the present study we analysed the different
Log-rank P= 0.24 aneuploid histograms and we disclosed a wide pattern of
abnormalities. Among these different patterns, multiploidy
and hypodiploidy were represented and the latter was
associated with a positive Ki-67 immunostaining suggesting
a link between high growth fraction and this abnormal
ploidy.
The effect of aneuploidy on the survival of patients with
lung cancer has been suggested by some studies (Bl6ndal and
60 80 100 Bengtsson, 1981; Volm et al., 1985; Abe et al., 1985;
Zimmerman et al., 1987; Salvati et al., 1988; Dazzi et al.,
1990), whereas others failed to demonstrate this relationship
(Bunn et al., 1983; Cibas et al., 1989; Cheon et al., 1993). We
survivat Censored (%) hypothesize that the prognostic significance of ploidy is not
47 shared by all aneuploid patterns. In our study, hypodiploidy
31 was the only aneuploid abnormality which independently
determined prognosis in lung cancer, particularly in NSCLC.
of lung cancer patients We conclude that hypodiploidy in lung cancer is a distinct
ation (hypodiploid vs other DNA content abnormality as it significantly contributes to
), hypodiploid. prognosis. Its detection might identify a distinct lung cancer
subgroup. These results deserve further studies aimed at
determining other relationships between hypodiploidy and
Table III Estimated hazard ratio ris
(P<0.05)
sk for significant variables clinical behaviour of lung cancer; chemosensitivity might be
one of them.
Variables Level of Boolean codage Hazard ratio 95% CI
Histology Small-cell vs non small-cell 6.501 2.880-14.67
Tumour T3 and T4 vs TI and T2 1.867 1.261-3.096
status
Nodal status NI and N2 vs NO 2.603 1.598-4.240
Ploidy Hypodiploid vs 2.070 1.041-4.116
non-hypodiploid
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